Get Premium to unlock powerful stock data
Alnylam Pharmaceuticals Inc logo

Alnylam Pharmaceuticals Inc

$ 127.26 -2.055 (-1.59%) 09:59 AM EST
P/E:
At Loss
P/B:
38.29
Market Cap:
$ 15.37B
Enterprise V:
$ 14.42B
Volume:
29.47K
Avg Vol (2M):
858.30K
Also Trade In:
Volume:
29.47K
Market Cap $:
15.37B
PE Ratio:
At Loss
Avg Vol (2-Month):
858.30K
Enterprise Value $:
14.42B
PB Ratio:
38.29
GF Score:
Year:
EMBED
To
10Y: -%
Above Low: +NaN%
Below High: NaN%

Business Description

Alnylam Pharmaceuticals Inc
NAICS : 325412 SIC : 2834
675 West Kendall Street, Henri A. Termeer Square, Cambridge, MA, USA, 02142
Description
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has four drugs on the market: Onpattro for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. The firm also has 12 clinical programs across the following therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Additionally, up-front fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.
Name Current Vs Industry Vs History
Cash-To-Debt 2.25
Equity-to-Asset 0.12
Debt-to-Equity 2.48
Debt-to-EBITDA -1.53
Piotroski F-Score 5/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 1.01
Distress
Grey
Safe
Beneish M-Score -2.87
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 50.36
9-Day RSI 41.7
14-Day RSI 39.9
6-1 Month Momentum % -3.12
12-1 Month Momentum % 23.14

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 4.27
Quick Ratio 4.14
Cash Ratio 3.7
Days Inventory 212.42
Days Sales Outstanding 62.5
Days Payable 134.62

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -5.9

Financials (Next Earnings Date:2022-08-03 Est.)

ALNY's 30-Y Financials

Guru Trades

See Details
To
EMBED
SAVE

Insider Trades

See Details
To
EMBED
SAVE

Gurus Latest Trades with NAS:ALNY

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To
EMBED
SAVE
Performance
Dividend
To
EMBED
SAVE

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

EMBED

Valuation Box

Year:
EMBED

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 879.98
EPS (TTM) ($) -7.49
Beta 0.61
Volatility % 42.75
14-Day RSI 39.9
14-Day ATR ($) 7.154423
20-Day SMA ($) 141.112
12-1 Month Momentum % 23.14
52-Week Range ($) 117.58 - 212
Shares Outstanding (Mil) 120.81

Piotroski F-Score Details

Component Result
Piotroski F-Score 5
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Alnylam Pharmaceuticals Inc Filings

Document Form Filing Date
No Filing Data

Headlines

See More